N-ratio: A novel independent prognostic factor for patients with stage-III cutaneous melanoma

被引:36
|
作者
Rossi, Carlo Riccardo [1 ]
Mocellin, Simone [1 ]
Pasquali, Sandro [1 ]
Pilati, Pierluigi [1 ]
Nitti, Donato [1 ]
机构
[1] Univ Padua, Dept Oncol & Surg Sci, I-35128 Padua, Italy
关键词
cutaneous melanoma; lymph node metastasis; N-ratio; prognostic factors;
D O I
10.1245/s10434-007-9641-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In this study, we tested the hypothesis that the ratio between metastatic and excised lymph nodes ("N-ratio") might have an independent prognostic value in patients with TNM stage-III cutaneous melanoma. Methods: The clinical records of 213 melanoma patients who had undergone radical lymph node dissection (RLND) and were found to harbor pathology-proven metastatic disease were used for analysis. The following clinico-pathological variables were considered for the prognostic study: patient's age and sex, primary tumor site, tumor thickness, Clark's level, ulceration, absolute number of positive lymph nodes, total number of excised lymph nodes, TNM stage (IIIA, IIIB, IIIC), and N-ratio (N-ratio A, <= 10%; N-ratio B, 10-25%; N-ratio C, > 25%). Results: Patients were categorized into three N-ratio classes according to the percentage of metastatic lymph nodes (N-ratio A, n = 94; N-ratio B, n = 95; N-ratio C, n = 24). The mean follow-up was 40 months. At univariate survival analysis, tumor thickness (P < 0.0001), ulceration (P = 0.046), Clark's level (P = 0.0002), number of positive lymph nodes (P < 0.0001), TNM stage (P < 0.0001), and N-ratio (P < 0.0001) were significantly associated with overall survival (OS). Interestingly, the Cox proportional hazard model showed that, along with tumor thickness (HR 1.069, P = 0.008) and TNM stage (HR 1.696, P = 0.015), N-ratio (HR 1.578, P = 0.012) also independently predicted OS. Conclusions: N-ratio is a novel easy-to-obtain independent prognostic factor for melanoma patients with lymph node metastases and might provide clinicians with additional information suitable for patient stratification while choosing adjuvant treatment. Validation of these results in larger prospective series is warranted to implement N-ratio in the routine clinical setting.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 50 条
  • [31] AN ANALYSIS OF SKIN-TESTS AND THEIR RELATIONSHIP TO RECURRENCE AND SURVIVAL IN STAGE-III AND STAGE-IV MELANOMA PATIENTS
    LEE, ET
    ISHMAEL, DR
    BOTTOMLEY, RH
    MURRAY, JL
    CANCER, 1982, 49 (11) : 2336 - 2341
  • [32] Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma
    Hansson, Johan
    Jovanovic, Braslav
    Krockel, Doris
    Linden, Diana
    Nilsson, Bo
    Egyhazi, Suzanne
    PIGMENT CELL & MELANOMA RESEARCH, 2008, 21 (02) : 285 - 285
  • [33] Lack of Cytoplasmic ERK Activation Is an Independent Adverse Prognostic Factor in Primary Cutaneous Melanoma
    Jovanovic, Braslav
    Kroeckel, Doris
    Linden, Diana
    Nilsson, Bo
    Egyhazi, Suzanne
    Hansson, Johan
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2008, 128 (11) : 2696 - 2704
  • [34] CLINICAL-EVALUATION OF LIPOSOMAL TUMOR-ANTIGEN VACCINES IN PATIENTS WITH STAGE-III MELANOMA
    PHILLIPS, NC
    LOUTFI, A
    AKAREEM, AM
    SHIBATA, HR
    BAINES, MG
    CANCER DETECTION AND PREVENTION, 1990, 14 (04): : 491 - 496
  • [35] DNA PLOIDY AND S-PHASE IN PRIMARY MALIGNANT-MELANOMA AS PROGNOSTIC FACTORS FOR STAGE-III DISEASE
    KARLSSON, M
    BOERYD, B
    CARSTENSEN, J
    KAGEDAL, B
    BRATEL, AT
    WINGREN, S
    BRITISH JOURNAL OF CANCER, 1993, 67 (01) : 134 - 138
  • [36] HUMORAL IMMUNE-RESPONSE TO ACTIVE SPECIFIC INTRALYMPHATIC IMMUNOTHERAPY IN PATIENTS WITH STAGE-III MELANOMA
    AHN, S
    JONES, P
    IRIE, R
    WEISENBURGER, T
    JUILLARD, G
    MORTON, DL
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 375 - 375
  • [37] In transit sentinel node drainage as a prognostic factor for patients with cutaneous melanoma
    Brandao, Paulo H. D. M.
    Bertolli, Eduardo
    Doria-Filho, Eduardo
    Santos Filho, Ivan D. A. O.
    de Macedo, Mariana P.
    Pinto, Clovis A. L.
    Duprat Neto, Joao P.
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (05) : 864 - 867
  • [38] Prognostic biomarkers based on melanoma cell-lines in stage III melanoma patients
    Knol, A. C.
    Nguyen, J.
    Pandolfino, M.
    Varey, E.
    Denis, M. G.
    Khammari, A.
    Dreno, B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S285 - S285
  • [39] ASO Author Reflections: Identification of Prognostic Factors for Stage-III Pancreatic Ductal Adenocarcinoma patients
    Chattopadhyay, Amrita
    Wu, Chien-Hui
    Tien, Yu-Wen
    Lu, Tzu-Pin
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (03) : 1616 - 1617
  • [40] Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
    Kakavand, Hojabr
    Scolyer, Richard A.
    Thompson, John F.
    Mann, Graham J.
    ONCOIMMUNOLOGY, 2013, 2 (09)